שווי פירמה כולל: Keros Therapeutics (KROS)

Keros Therapeutics (KROS) is an American biopharmaceutical organization developing therapies for bone and blood pathologies. The business relies on an asset-light model: scientific research is conducted in-house, while the production of biologics is delegated to major contractors. The asset value tracked on this chart, which currently stands at -22.99, depends on clinical trial outcomes and is not subject to the influence of the global economy.

Keros Therapeutics (KROS) develops TGF-beta protein regulators for the treatment of lung and blood diseases. By analyzing the current EV, an investor sees the total cost of acquiring the business adjusted for net debt. This metric sums the market capitalization and liabilities, minus cash and cash equivalents. For biopharmaceuticals with binary clinical risks, this serves as a measure of the assets' real price. The trend of this indicator helps determine whether there is an overpayment for the pipeline's potential.